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A novel gangliaside was detected in a small cell lung carcinoma by TL~-jmmunostai~ing of gangIiosides 
with a monoclonal antibody, the C-50 MAb. Structural characterization showed this ganglioside to be 
IV3NeuAc-LcOse,Cer, a hitherto unknown ganglioside. This ganglioside has also been detected as  minor 
component in many different carcinomas using the C-50 MAb. The normally dominant CA-50 ganglioslde 
antigen is IV3NeuAc, IIIYuc-LcOse,Cer. Based upon solid-phase binding to IV3NeuAc, IIIQLcQse,Cer 
and IV~~euA~-~Us~~~er it is concfuded that the C-50 MAb recognizes an epitope present in sialylated 
type 1 carbohydrate chains. 
Carcinoma-associated gangliaside 
1. iNTR~DUCTl~N 
The introduction of the hybridoma technology 
of Kijhler and Milstein [l] has dramatically im- 
proved the possibilities for detecting and defining 
tumour-associated antigens. Marked changes of 
the gly~ol~pid composjtjon of cells occur during 
oncogenic transformations and different tumour- 
associated glycolipid antigens have been identified 
using monaclonal antibodies [2-51. A previous 
report has described monoclonal antibodies defin- 
ing carcinoma-associated ganglioside antigens ob- 
tained after immunization with the color&al 
adenocarcinoma cell line COLO 205 @]. One of 
these antibodies, the C-50 MAb, has been studied 
more extensively and has been shown to detect an- 
tigens with generalized carcinoma distribution 
[7,8]. The CA-50 ganglioside antigen present in the 
COLU 20.5 cell line has been characterized as 
IV3NeuAc, II14Fuc-LcOse&Zer (sialosylfucosy~la~~ 
totetraosylceramide, Fuciso 3 ’ LMI) (M&Won, 
J.-E. et al., submitted), which is the sialylated 
Lewisa pentaglycosylceramide characterized by 
A bbre~iat~o~s: The gangliosides have been designated 
according to [25] 
Magnani et al. [4]. This paper describes the isola- 
tion and characterization of a ‘novel’ CA-50 anti- 
gen. 
2. EXPERIMENTAL 
Tumour tissue was obtained at autopsy from a 
71-year-old smoker who died from small cell lung 
carcinoma with multiple metastases. Histopatho- 
logical examination established the diagnosis as 
oat cell type of small cell carcinoma, Only the 
primary tumour was available for analysis. 
The C-50 monoclonal antibody was obtained by 
intravenous immunization of mice with the colo- 
rectal adenocarcinoma cell line COLO 205 (Ameri- 
can Type Culture Collection, Rockville, MD), and 
fusion between spleen cells from the immunized 
mice and Sp 2/O cells [B]. The C-50 MAb was 
purified from culture medium by ammonium sul- 
phate precipitation, and used in a concentration of 
approx. lpg/ml. The 19-9 MAb [Z3] was a gift 
from Dr P. Burtin, lnstitut de Recherches Scien- 
tifiques, Villejuif, France; it was used at a concen- 
tration of approx. lag/ml. Affinity purified goat 
anti-mouse IgM immunoglobulin was obtained 
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from Kirkegaard and Perry, Gaithersburgh, MD, 
and ‘251-labelled to a specific activity of 20-60 
&i/&g using the IodogenR method 191. i2%- 
labelled anti-mouse F(ab)z fragment was obtained 
from The Radiochemical Centre, Amersham. 
Silica gel 60,230-400 mesh; glass-backed TLC and 
HPTLC plates, silica gel G; and alumina-backed 
HPTLC plates, silica gel G, were all from Merck, 
Darmstadt, FRG. Sephadex G-25 fine was from 
Pharmacia, Uppsala, Sweden. The anion exchange 
resin Spherosil-DEAE-dextran was a gift from In- 
stitut Merieux, Lyon, France [lo]). Vibrio cholerae 
sialidase (EC 3.2.1.18) was from Behringwerke, 
Marburgh-Lahn, FRG. All organic solvents and 
other chemicals were of analytical quality and used 
without further purification, Gangliosides used as 
standards and references were all isolated at the 
Department of Psychiatry and Neurochemistry, 
University of Goteborg. 
2.2. ~sotat~on of gang~iosides 
The tumour tissue (75 g) was homogenized in a 
scissor homogenizer in 3 vols (w/v) distilled water, 
and extracted twice with 20 vols chloroform/ 
methanol/water (C/M/W; 4 : 8 : 3, (v/v) [l 11. The 
total lipid extract was evaporated to dryness and 
dissolved in C/M/W (60: 30:4.5). Low molecular 
mass contaminants were removed by gel filtration 
on Sephadex G-25 [ 121. Gangliosides were isolated 
and separated into mono- and oligosialoganglio- 
sides by eultion from the anion exchange resin 
Spherosil-DEAE-dextran with a discontinuous 
gradient of potassium acetate in methanol [IO]. 
The monosialoganglioside fraction was purified 
by alkaline methanolysis in 0.5 M KOH in 50% 
methanol, followed by column chromatography 
on Silica Gel 60, 230-400 mesh. The column was 
eluted with C/M/W, 65 :25 :4, until all ganglio- 
sides with a TLC migration corresponding to GM3 
and GM2 were eluted, as monitored by HPTLC 
analysis of the eluate. The solvent was then 
changed and the column eluted with 10~01s 
C/M/W, 60: 35 :8; the eulate was subsequently 
collected as one fraction. Individual gangliosides in 
the 60: 35 : 8 fraction were isolated by preparative 
TLC using n-propanoY2.0M ammonia in 0.25% 
aq. KCl, 7 : 3 (v/v) as developing solvent. 
The isolation of the CA-50 ganglioside antigen 
was monitored by TLC-immunostaining, essential- 
ly as described by Brockhaus et al. [ 13]. 
2.3. Structural analyses of the CA-50 ganglioside 
antigen 
Sialic acid was determined with the resorcinol 
assay [ 141, and sphingosine bases were assayed 
with a modified methyl orange method [lS]. Siali- 
dase hydrolysis and acidic hydrolysis were per- 
formed as described in [ 161. The carbohydrate 
composition was quantitatively determined by 
GLC of the corresponding alditol acetates [17]. 
The ganglioside was permethylated according to 
Hakomori [ 181, and the individual sugars analysed 
as their corresponding partially methylated alditol 
acetates by GC-MS [19]. 
2.4. ~eter~inafio~ of C-50 and 19-9 reactivity 
The reactivity of the C-50 MAb against differ- 
ent gangliosides was determined by a solid-phase 
double antibody radioimmunoassay with the 
gangliosides adsorbed to the wells of polyvinyl 
microtiter plates [20]. The reactivity of the C-50 
MAb against the CA-50 ganglioside antigen frac- 
tion isolated from this case was compared with the 
C-50 reactivity against sialosylfucosyllactotetrao- 
sylceramide (IV3NeuAc-II14Fuc-LcOse4Cer) iso- 
lated from COLO 205 cells and with 3’ LMl 
(IV3NeuAc-nLcOse&er) isolated from erythro- 
cytes [21]. The reactivity of the 19-9 MAb was also 
tested against sialosylfucosyllactotetraosylcera- 
mide and the CA-SO ganglioside fraction isolated 
from this tumour. 
3. RESULTS AND DISCUSSION 
TLC-immunostaining of gangliosides with the 
C-50 MAb showed that this tumour contained a 
CA-50 ganglioside antigen with a faster TLC 
migration than that present in the COLO 205 cells 
(fig. 1). A ganglioside with the same chromato- 
graphic mobility can be detected as a minor CA-SO 
ganglioside antigen in various carcinomas, but this 
is the first case analysed thus far in which the fast 
migrating CA-50 ganglioside antigen was the quan- 
titatively dominant CA-50 ganglioside antigen. 
The ganglioside was isolated to apparent homo- 
geneity by combined silica column chromato- 
graphy and preparative TLC, based upon C-SO 
TLC-immunostaining and TLC-analysis (fig. 1,2). 
The isolated ganglioside contained sphingosine, N- 
acetylneuraminic acid, glucose, galactose and 
glucosamine in the molar ratio 1: 1: 1: 2 : 1. Hydro- 
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Fig. 1. C-50 TLC-immunostaining of monos~aloganglio- 
sides isolated from a smail cell lung carcinoma. The 
gangliosides were separated on aiumina-backed HPTLC- 
plates developed C/M/0.25% KC1 (5 :4: 1). The im- 
munostaining was performed as in [13]. Lane 1, 25 pmol 
of total monosialogangliosides i olated from COLO 205 
cells; upper band IV3NeuAc,li14Fu~-LcOse~Cer, lower 
band IV3N~uAc,V3Fuc-L~Ose~Cer; lanes 2,3, total 
monosialogangliosides from the small cell lung car- 
cinoma corresponding to 5 and 10 mg tissue, respective- 
ly; lanes 4,5 C/M/W (60:35:8) fraction from the silica 
column, 5 and IOmg tissue, respectively; lanes 67, 
purified CA-SO ganglioside, 5 and 1Omg tissue, res- 
pectively. 
lysis with sialidase or weak acid yielded a tetra- 
glycosylceramide with a similar TLC-migration as 
neolactotetraosylceramide. Prolonged acid hydro- 
lysis produced compounds with the same mobility 
on TLC as lactosylceramide and glucosylceramide. 
The results of the methylation analysis of the in- 
tact ganglioside and the desialylated substance are 
shown in table 1. The finding of both 4,6-Mel- 
GlcNAcMe and 3,6-Me2-GlcNAcMe indicated that 
the isolated ganglioside was not homogeneous, but 
contained gangliosides related to both the lacto- 
tetraose and the neolactotetraose series. The rela- 
tive ratio of 4,6-Mez-GlcNAcMe and 3,6-Me2- 
GlcNAcMe was approx. 4: 1. When the desialyl- 
ated substance was analyzed, 2,3,4,6-Me4-Gal ap- 
peared, which indicated that the sialic acid was at- 
tached in a terminal NeuAti2-3Gal linkage. A 
combination of the structural analyses suggests 
that the C-50 reactive ganglioside isolated from 
this tumour contained as the dominant constituent, 
IV3NeuAc-LcOse4Cer (sialosyllactotetraosylcera- 
mide, 3 ’ -isoLM 1) and IV3NeuAc-nLcOse&er 
Gak3-3GlcNAc&1-3Gal,&-4Gl~1-lceramide 
3 
Neu Acui 
IV3NeuAc-LcOs%Cer, sialosyllactotetraosylceramide. 
(sialosylneolactotetraosylceramide, 3 ’ LM I). Sialo- 
syllactoteraosylceramide has not been isolated and 
characterized previously. However, Falk et al. [22] 
had indications of the existence of this ganglioside 
in a pancreatic adenocarcinoma. This compound 
represents the second ganglioside based on the lac- 
totetraose structure characterized to date. 
The C-SO reactivity against the CA-50 gan- 
glioside fraction isolated from this tumour; 
IV3NeuAc,1114Fuc-LcOsedCer isolated from 
COLO 205 cells; and 3 ’ LMI isolated from 
human erythrocytes [21], is shown in fig.3A. As 
the C-50 MAb did not react with the 3 ’ LMl, it is 
concluded that the CA-50 ganglioside antigen 
isolated from this tumour was IV’NeuAc- 
LcOsesCer. Thus the C-50 MAb recognized as 
epitope present both in IV3NeuAc-LcOsedCer and 
in IV3NeuAc,II14Fuc-LcOse4Cer. The sialic acid 
was an absolute requirement for antigenicity, as 
sialidase hydrolysis of the ganglioside completely 
abolished the binding of the C-50 MAb (Nilsson, 
0. et al., in preparation), while the fucose residue 
was not necessary for binding (fig. 3A). The reac- 
Table 1 
Results of the permethylation analysis of the CA-SO ganglioside antigen isolated from a case of small cell lung carcinoma 
and of the corresponding desialylated glycolipid 
2,3,4,6-Me4 3,6-Me2 4,6-Me2 2,4,6-Me3 2,3,6-Me3 
Gal GlcNAcMe GlcNAcMe Gal Glc 
Ganglioside 0 (+) + + + 
Desialylated 
glycolipid + (+) + + + 
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Fig.2. Chemical staining of monosialogangliosides i olated from a small cell lung carcinoma. The gangliosides were 
isolated as described in section 2. They were separated in C/M/W, 5 : 4 : 1, and visualized with resorcinol spray. Lane 
1, total monosialogangliosides; lane 2, C/M/W (60 : 35 : 8) fraction; lane 3, purified CA-SO ganglioside (see fig. 1, lanes 
67). 
tivity of the C-50 MAb was approx. lo-times 
higher for IV3NeuAcII14Fuc-LcOse4Cer compared 
with IV3NeuAc-LcOsedCer determined with the 
solid-phase assay used here. 
‘*- A 
32 0 2 0.5 0125 0.007 
pmol NeuAc 
‘*’ B 
32 8 2 0.5 0.125 0.007 
pmol NeuAc 
Fig.3. Solid-phase binding of (A), C-50 MAb, (B) 19-9 MAb, to gangliosides. The assay was performed as described 
in section 2. (0) IV3NeuAc,II14Fuc-LcOse4Cer isolated from COLO 205 cells; (e) CA-50 ganglioside fraction isolated 
from the carcinoma described in this paper; this fraction contained -80% IV3NeuAc-LcOseACer and 20% 3 ’ LM 1; (A) 
3 ’ LM 1 isolated from erythrocytes. 
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Koprowski et al. [23] described a monoclonal 
antibody, the 19-9 MAb, which defines the 
IV3NeuAcII14Fuc-LcOse&er (S-Lea pentaglyco- 
sylceramide) [4]. The fucose and the sialic acid 
residue have been established to be involved in the 
recognition structure of the 19-9 MAb [24], which 
was also indicated by the negligible reactivity of 
the 19-9 MAb with the sialosyllactotetraosylcera- 
mide (fig.3B). The 19-9 MAb would then seem to 
define an epitope different from that defined by 
the C-50 MAb. 
&I 
171 
PI 
The CA-50 ganglioside antigen, present in the 
COLO 205 cell line (Mansson, J.-E. et al., submit- 
ted and the normally dominant CA-50 ganglioside 
in carcinomas (IV3NeuAc,II14Fuc-LcOSe4Cer) is 
related to the expression of the Lewis gene and 
would not be expressed in Lewis negative indi- 
viduals. Lewis negative subjects lack the fucosyl 
transferase transferring the fucose residue to the 
glucosamine, but can synthesize lactotetraosylcera- 
mide. The Lewis status of the present case was not 
determined, but one explanation for the presence 
of sialosyllactotetraosylceramide as the only CA- 
50 ganglioside antigen could be that the subject 
was Lewis negative. 
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